International Study to Predict Optimized Treatment for Depression (iSPOT-D)
Author Information
Author(s): Leanne M Williams, John A Rush, Stephen H Koslow, Stephen R Wisniewski, Nicholas J Cooper, Charles B Nemeroff, Alan F Schatzberg, Evian Gordon
Primary Institution: BRAINnet Foundation
Hypothesis
The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine.
Conclusion
iSPOT-D aims to identify moderators and predictors of treatment response among three treatments: escitalopram, sertraline, and venlafaxine-XR.
Supporting Evidence
- Major depressive disorder (MDD) is the fourth most disabling medical condition worldwide.
- Only about 50% of patients with MDD show a response to antidepressant medications.
- The study aims to mirror clinical practice in a representative spectrum of outpatients.
Takeaway
This study is trying to find out what factors can help predict how well different depression treatments work for people.
Methodology
The study is a multi-centre, international, randomized, prospective, open-label trial enrolling 2016 MDD outpatients.
Potential Biases
Potential biases may arise from the open-label design and the reliance on self-reported measures.
Limitations
The study excludes patients over age 65 and adolescents/children due to potential interactions with medications.
Participant Demographics
Participants are MDD outpatients aged 18-65, with a mix of genders and educational backgrounds.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website